Liquidia (LQDA) Net Income towards Common Stockholders (2020 - 2026)

Liquidia's (LQDA) quarterly Net Income towards Common Stockholders came in at $52.9 million in Q1 2026, up 237.83% year-on-year from $15.7 million in Q1 2025, and up 263.33% quarter-over-quarter from $14.6 million in Q4 2025.

Liquidia (LQDA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Liquidia's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at $52.9 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 237.83% year-over-year to $52.9 million in Q1 2026; TTM through Mar 2026 was -$186.9 million, a 23.86% increase from a year earlier, with the FY2025 full-year figure at -$293.7 million, down 28.44% from the prior year.
  • Net Income towards Common Stockholders grew to $52.9 million in Q1 2026 per LQDA's latest filing, from $14.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $52.9 million in Q1 2026 and bottomed at -$149.9 million in Q3 2025.
  • The 5-year median for Net Income towards Common Stockholders is -$31.2 million (2023), against an average of -$43.9 million.
  • Across the five-year window, Net Income towards Common Stockholders slumped 293.38% in 2024 and soared 237.83% in 2026, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$6.5 million in 2022, then sank by 229.66% to -$21.5 million in 2023, then slumped by 78.81% to -$38.5 million in 2024, then jumped by 137.8% to $14.6 million in 2025, then soared by 263.33% to $52.9 million in 2026.
  • Per Business Quant, the three latest LQDA Net Income towards Common Stockholders figures stand at $52.9 million (Q1 2026), $14.6 million (Q4 2025), and -$149.9 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 89.91 Bn 88.04 Bn - -
2 Teva Pharmaceutical Industries 35.91 Bn 32.17 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.54 Bn 30.60 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.54 Bn 23.48 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 23.05 Bn 20.89 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 21.48 Bn 21.48 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.82 Bn 16.50 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 57.00 Mn
10 Liquidia 7.59 Bn 7.36 Bn 121.79 Mn 52.88 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 52.88 Mn
Dec 31, 2025 14.56 Mn
Sep 30, 2025 -149.91 Mn
Jun 30, 2025 -104.39 Mn
Mar 31, 2025 -38.37 Mn
Dec 31, 2024 -38.51 Mn
Sep 30, 2024 -75.21 Mn
Jun 30, 2024 -93.32 Mn
Mar 31, 2024 -121.96 Mn
Dec 31, 2023 -21.54 Mn
Sep 30, 2023 -31.18 Mn
Jun 30, 2023 -53.03 Mn
Mar 31, 2023 -31.00 Mn
Dec 31, 2022 -6.53 Mn
Sep 30, 2022 -19.38 Mn
Jun 30, 2022 -14.35 Mn
Mar 31, 2022 -15.82 Mn
Dec 31, 2021 -11.56 Mn
Sep 30, 2021 -13.74 Mn
Jun 30, 2021 -7.96 Mn